Targeted Thoracic Immuno-Oncology: Amgen’s DLL3-Directed T-Cell Engager Imdelltra® (Tarlatamab) Demonstrates Landmark Overall Survival Improvement in Phase 3 DeLLphi-305 Trial – Establishing New First-Line Maintenance Paradigm in Extensive-Stage SCLC

Key Development

On September 8, 2026, biotechnology leader Amgen (NASDAQ: AMGN) reported headline outcomes from a pre-specified interim analysis of its pivotal global Phase 3 DeLLphi-305 clinical trial (NCT06211036).

The trial assessed the therapeutic efficacy of its first-in-class DLL3-targeted bispecific T-cell engager (BiTE) Imdelltra® (tarlatamab-dlle) administered in combination with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) as a first-line maintenance intervention for patients with extensive-stage small cell lung cancer (ES-SCLC):

• Primary Endpoint Attainment (Overall Survival – OS): The combination regimen of Imdelltra plus Imfinzi demonstrated a statistically significant and clinically meaningful prolongation of overall survival compared against standard maintenance durvalumab monotherapy.

• Key Secondary Efficacy Endpoints: The investigational regimen demonstrated statistically significant improvements across progression-free survival (PFS) and objective response rate (ORR).

• Clinical Trial Architecture and Patient Stratification: The trial enrolled 563 adult patients diagnosed with ES-SCLC across international study centers. Enrolled participants had demonstrated non-progressive disease following standard frontline platinum-based induction chemotherapy (carboplatin or cisplatin plus etoposide) administered concurrently with durvalumab. Patients were randomized 1:1 to receive maintenance Imdelltra plus Imfinzi or Imfinzi monotherapy until confirmed radiological progression or unacceptable toxicity.

• Safety and Tolerability Profile: The safety profile of the dual regimen was consistent with the established toxicities of each monotherapy, with no new safety signals observed. Routine step-up dosing administration protocols were applied to mitigate the incidence of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

• Regulatory Filing Roadmap: Amgen announced plans to submit the complete DeLLphi-305 dataset to the U.S. FDA, the European Medicines Agency (EMA), and other health authorities, while presenting detailed data at an upcoming oncology medical congress.

Why It Matters

• Advancing targeted immunotherapy into earlier treatment settings: Small cell lung cancer accounts for 13% to 15% of the 2.6 million lung cancer diagnoses recorded worldwide annually and is characterized by early metastasis and chemoresistance. Real-world clinical registries confirm that only roughly 40% of ES-SCLC patients maintain the functional performance status required to receive second-line (2L) intervention. Moving Imdelltra into the frontline maintenance phase captures the broader patient population that would otherwise experience disease progression or clinical deterioration prior to subsequent treatment.

• Landmark validation for T-cell engagers in solid oncology: DeLLphi-305 represents the first Phase 3 clinical trial in solid oncology to confirm a statistically significant overall survival benefit for a bispecific T-cell engager administered in a first-line maintenance setting.

• Re-evaluating frontline maintenance benchmarks: Current benchmarks in frontline ES-SCLC maintenance were established by the IMforte trial, in which Jazz Pharmaceuticals’ Zepzelca® (lurbinectedin) combined with Roche’s Tecentriq® (atezolizumab) yielded an OS of 13.2 months versus 10.6 months for atezolizumab alone. In earlier Phase 1b DeLLphi-303 evaluations, Imdelltra combined with anti-PD-L1 therapy generated a median OS of 25.3 months, underscoring the clinical interest in the forthcoming DeLLphi-305 numerical readouts.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, the DeLLphi-305 Phase 3 readout on September 8, 2026, illustrates Bispecific T-Cell Engager Frontline Integration and Precision Immuno-Oncology Maintenance.

The clinical findings highlight three strategic oncology principles:

1. Target specificity of Delta-like ligand 3 (DLL3): DLL3 exhibits high surface expression across 85% to 96% of small cell lung cancer tumors, while exhibiting minimal expression on healthy somatic tissues. This differential expression enables Imdelltra’s dual-affinity construct (binding DLL3 on malignant cells and CD3 on cytotoxic T lymphocytes) to direct targeted T-cell-mediated lysis while sparing surrounding tissue.

2. Synergistic mechanisms of T-cell activation and checkpoint inhibition: Combining a BiTE platform with a PD-L1 inhibitor addresses common immune evasion pathways. While Imdelltra bridges cytotoxic T cells directly to DLL3-positive neuroendocrine tumor cells, durvalumab inhibits PD-1/PD-L1-mediated T-cell exhaustion, helping sustain active immune surveillance during the post-chemotherapy maintenance window.

3. Sustaining competitive leadership in the DLL3 race: Following accelerated approval in 2024 and full second-line approval in 2025 based on the DeLLphi-304 trial, securing first-line Phase 3 validation reinforces Amgen’s first-mover advantage. This clinical progress raises technical and regulatory bars for competing DLL3 platforms currently in clinical development (including Merck’s MK-6070, Boehringer Ingelheim’s obrixtamig, Roche/Innovent’s ADC, and AbbVie/Zejing’s trispecific constructs).

Market Implications

1. Expansion of Imdelltra’s addressable patient population: Securing frontline maintenance approval will expand the commercially addressable SCLC patient pool compared to the second-line setting, supporting long-term revenue growth for Amgen’s oncology portfolio.

2. Reinforcing AstraZeneca’s Imfinzi as a frontline standard: The success of the combination regimen supports the continued clinical use of Imfinzi (durvalumab) as a backbone immunotherapy in ES-SCLC, helping defend its position in the first-line setting.

3. Clinical practice guideline revisions: Topline DeLLphi-305 data are anticipated to drive updates to international clinical guidelines (such as NCCN and ESMO), informing treatment recommendations for extensive-stage SCLC maintenance therapy.

Clinical Trial Summary Matrix: Phase 3 DeLLphi-305 (Amgen & AstraZeneca)

Source: https://www.fiercepharma.com/pharma/amgen-dll3-targeted-imdelltra-scores-overall-survival-win-first-line-small-cell-lung-cancer